---
title: "Envoy Medical, Inc. Q2 2026: Revenue $51K, Net loss $5982K — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295409143.md"
description: "Envoy Medical reported Q2 2026 revenue of $51K and a net loss of $5,982K. The company completed enrollment in its Acclaim cochlear implant pivotal trial and initiated a modular PMA submission with the FDA. R&D spending increased due to trial expansion and commercialization preparations. Revenue remains nominal from legacy products as the firm focuses on regulatory approval for Acclaim CI, with a decision expected in H2 2027 or later."
datetime: "2026-08-10T12:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295409143.md)
  - [en](https://longbridge.com/en/news/295409143.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295409143.md)
generator: "portal-rs"
---

# Envoy Medical, Inc. Q2 2026: Revenue $51K, Net loss $5982K — 10-Q Summary

Envoy Medical, Inc. reported second-quarter 2026 results marked by nominal revenue and a widening net loss as the company continued to invest in its Acclaim cochlear implant pivotal trial and regulatory pathway.

**Financial Highlights**

-   Revenue: $51K for Q2 2026, down from $78K in the year-ago quarter ( (34.6%) ).
-   Net income: Net loss $5,982K for Q2 2026 vs. net loss $5,690K in the year-ago quarter (loss widened $292K, (5.1%)).
-   Diluted EPS: Not reported for the quarter; diluted EPS not provided in Part I Items 1–2.

**Business Highlights**

-   Clinical milestone: Completed enrollment of the 56‑patient Acclaim CI pivotal trial; all patients passed the 3‑month milestone and the first 10 patients reached 12 months.
-   Regulatory pathway: Begun a modular PMA submission with the first module filed; the company expects to file the full PMA after collection of all 12‑month data with a decision likely in H2 2027 or later if a panel is required.
-   R&D and operations: R&D spending increased as the trial expanded to Stage 2, with higher clinical and product-related costs and reallocation of field clinical engineers to support the trial and commercialization preparations.
-   Revenue mix and commercialization: Revenues remain nominal and derived from legacy Esteem FI‑AMEI implants while the company shifts focus almost entirely to Acclaim CI development and future commercial build‑out, with plans to scale sales and marketing pending regulatory approval.

Original SEC Filing: Envoy Medical, Inc. \[ COCH \] - 10-Q - Aug. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [COCH.US](https://longbridge.com/en/quote/COCH.US.md)
- [COCHW.US](https://longbridge.com/en/quote/COCHW.US.md)

## Related News & Research

- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [SoftwareOne attaches full H1 2026 report in correction to earlier release](https://longbridge.com/en/news/297010247.md)
- [Omda to present Q2 2026 results via webcast](https://longbridge.com/en/news/297024929.md)
- [Equifax declares Q3 2026 distribution of R$ 2.02 per unit, payable Sept. 22](https://longbridge.com/en/news/296941296.md)
- [Cemat publishes H1 2026 interim report](https://longbridge.com/en/news/297006906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**